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This study was undertaken to evaluate the differences in chronotherapeutic effects of angiotensin-II
receptor blockers, valsartan and olmesartan in hypertensive patients with non-dipper blood pressure
(BP) pattern during valsartan at morning. Ninety four patients were enrolled, and 40 patients were
judged to be non-dippers. In these patients, same dose of valsartan was changed to evening (Val-E,
n ¼ 12), or olmesartan (equivalent dose of valsartan) was given at morning (Olm-M, n ¼ 13) or evening
(Olm-E, n ¼ 15) for 4 months. BP decreased during sleep and increased during waking hours in Val-E
group. In Olm-M and Olm-E groups, BP decreased during sleep and waking hours. Percent reduction
in BP at night-time compared to BP at waking hours signiﬁcantly increased after changing the dose
regimen in each group. Serum creatinine decreased and estimated glomerular ﬁltration rate (eGFR)
elevated in Olm-M and Olm-E, but not Val-E groups. Positive correlation between systolic BP (SBP)
during sleep and serum creatinine, and negative correlation between SBP during sleep and eGFR were
detected. These data suggest that dipper BP pattern could be obtained by chronotherapeutic approach
using valsartan and olmesartan in non-dipper patients with valsartan at morning. Morning and evening
olmesartan, but not evening valsartan improved renal function in these patients.
© 2014 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronotherapy is a pharmacologic approach whereby a drug is
given at a time that varies according to physiologic needs. Our
previous study using stroke-prone spontaneously hypertensive rats
(SHR-SP) showed that blood pressure (BP)-lowering effect of val-
sartan [an angiotensin-II receptor blocker (ARB)] was longer after
dosing at an inactive period than after dosing at an active period
and, consequently, the survival period of the animals was longer
after dosing at an inactive period (1). However, such effects based: þ81 285 44 7562.
acological Society.
. Production and hosting by Elseon the time of dosing were not observed for another ARB, olme-
sartan in this animal study. Duration of BP-lowering effect in
SHR-SP and prolongation of their survival period after dosing
olmesartan at an active period were similar to those after dosing
the drug at an inactive period (1). These animal data led us to
speculate that the chronotherapeutic effects of valsartan were
different from those of olmesartan in hypertensive patients.
There are precedents for chronotherapy in hypertension in
clinical practice. For example, Hermida et al. reported that, in un-
treated hypertensive patients with a non-dipper BP pattern, a
dipper BP pattern was obtained in 24% and 75% of patients after
dosing of valsartan in the morning and evening, respectively (2).
Recent advances in ambulatory blood pressure monitoring
(ABPM) have demonstrated that a higher night-time BP and a non-vier B.V. This is an open access article under the CC BY-NC-ND license (http://
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and progression of renal disease (5,6). Cardiovascular morbidity
and mortality are also reported to elevate in hypertensive patients
with a non-dipper BP pattern even under antihypertensive drugs
(7). These data suggest that it is important for changing a non-
dipper to dipper BP pattern in hypertensive patients. Previous
studies showed that switching dosing-time of antihypertensive
drugs for morning to evening in patients with a non-dipper BP
pattern during morning treatment caused more BP reduction at
night-time and increased a number of dipper BP pattern (8e10).
Valsartan is one of ARBs, which are frequently prescribed for the
treatment of hypertension and improve the prognosis of patients.
However, a non-dipper BP pattern is detected in half (46~58%) of
hypertensive patients after dosing of valsartan in the morning
(11,12), and therefore, a chronotherapeutic approach might provide
a beneﬁt for these patients. To address the issue and potential
chronotherapeutic differences between valsartan and olmesartan,
this study was performed in hypertensive patients with a non-
dipper BP pattern during morning treatment with valsartan as
follows; 1) a dosing-time was switched from morning to evening,
and 2) ARB was changed to olmesartan, which was given at
morning or evening. To evaluate a beneﬁt of chronotherapy, the
inﬂuences on BP pattern and renal function were determined in
each group.
2. Methods
The study protocol was approved by the Ethics Review Board of
Jichi Medical University (Tochigi, Japan), and registered with the
University Hospital Medical Information Network Clinical Trials
Registry, Tokyo, Japan (registration number UMIN000003776). This
study was conducted in accordance with the Declaration of Hel-
sinki. Written informed consent was obtained from each patient.
Hypertension was deﬁned as systolic BP (SBP)  140 mmHg
and/or diastolic BP(DBP)  90 mmHg at clinic. The deﬁnition of
night-time BP dipping was based on SBP; night SBP > day SBP as a
“riser”, and [1-night SBP/day SBP]  100 (%): 0 ratio <10 as aFig. 1. Study design and number of patients, (a) Patients withdrew their informed consent, (b
was changed during the study.“non-dipper”; 10 ratio <20 as a “dipper”, and 20 ratio as an
“extreme dipper” (13).
The inclusion criteria were as follows; (i) Hypertensive patients
took 40e160 mg valsartan once daily in the morning for
>2 months; (ii) Dose regimens of valsartan and other antihyper-
tensive drugs were not altered for >2 months, and clinic BP was
well controlled (SBP <140 mmHg and DBP <90 mmHg in non-
diabetic patients, and SBP <130 mmHg and DBP <80 mmHg in
diabetic patients); (iii) Identical dose regimens for hypertension
and comorbidities could continue for the following 4 months; (iv)
Shift workers were not included; (v) Patients had a non-dipper BP
pattern during morning dosing of valsartan.
2.1. Patients
All patients were active during day-time, and took a rest during
night-time. Ninety four hypertensive patients were enrolled in the
study (Fig. 1). Patients were initially diagnosed as being hyperten-
sive based on clinic BP measurement. The dosing-time of valsartan
and other antihypertensive drugs was morning in all patients,
except for two patients: one took azelnidipine in the morning and
evening, and another took amlodipine at bedtime.
2.2. Study design
The study had a multicenter, open-label, randomized, parallel-
group design. The 24-h assessment of BP was done with a
portable automatic ABPM device (TM-2431; A&D Co., Ltd., Tokyo,
Japan). BP measurements were taken every 30 min from 6 am to 10
pm, and every 60min from 10 pm to 6 am, to obtain 24-h, day-time,
and night-time data. BP data were analyzed using software (TM-
2430; A&D Co., Ltd.). “Day-time” and “night-time” were judged
based on the diary of each patient.
Two patients withdrew their consent to be included in the study
(Fig. 1). The ﬁrst 24-h BP was assessed in the remaining 92 subjects:
52 patients were judged to be “dippers” and the remaining 40
patients to be “non-dippers”. The latter (40/92; 43%) were divided) Laboratory examinations were not undertaken at 4 months, (c) Antihypertensive drug
Table 1
Characteristics of hypertensive patients at the initiation of the study.
Reference group Randomization group
Valsartan-M Valsartan-E Olmesartan-M Olmesartan-E
Number
(male/female)
43 (28/15) 11 (7/4) 11 (4/7) 12 (5/7)
Age (years) 64.6 ± 9.3 63.2 ± 13.8 64.3 ± 13.0 66.2 ± 7.0
Body weight (kg) 65.7 ± 13.6 65.8 ± 12.6 62.0 ± 6.4 61.0 ± 15.1
Co-morbidity (n)
Diabetes 2 3 1 4a
Dyslipidemia 10 3 2 3
Dose of Valsartan (n)
40 mg 21 5 7 8
80 mg 20 6 4 4
160 mg 2 0 0 0
Co-medication (n)
Ca-blocker 16 3 2 3
Diuretics 3 1 2 1
b-blocker 2 0 0 0
Ca-blocker þ
diuretics
2 1 0 2
Ca-blocker þ
b-blocker
3 1 2 1
Mean ± S.D.
a p < 0.05 vs. Valsartan-M.
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olmesartan-morning dosing (olmesartan-M) (n ¼ 13) and
olmesartan-evening dosing (olmesartan-E) (n ¼ 15) groups. The
inhibitory action of olmesartan on angiotensin-II labeled with
iodine-125 bound to the angiotensin-II receptor type 1 is reported
to be about fourfold greater than that of valsartan (14). In clinical
practice, the recommended starting dose is 80mg/day for valsartan
and 20 mg/day for olmesartan (15). Based on these basic and
clinical data, the dose of olmesartan was one quarter that of val-
sartan in olmesartan-M and olmesartan-E groups (e.g., 80 mg/dayTable 2
Proﬁles of blood pressure (BP) at the initiation and end of the study.
Reference group Randomi
Valsartan-M (n ¼ 43) Valsartan
At the initiation of the study
Duration of sleep (h) 7.4 ± 1.3 6.4 ± 1
SBP reduction at night-time (%) 16.6 ± 5.7 2.4 ± 6
BP during waking hours
SBP (mmHg) 143.6 ± 11.3 136.1 ± 9
DBP (mmHg) 87.1 ± 8.3 82.8 ± 5
BP during sleep
SBP (mmHg) 119.6 ± 10.6 132.9 ± 1
DBP (mmHg) 73.3 ± 7.4 79.2 ± 7
24-h BP
SBP (mmHg) 138.3 ± 11.2 135.4 ± 9
DBP (mmHg) 83.4 ± 7.5 82.2 ± 5
At the end of the study
Duration of sleep (h) 7.4 ± 2
SBP reduction at night-time (%) 10.5 ± 3
BP during waking hours
SBP (mmHg) 144.0 ± 1
DBP (mmHg) 87.0 ± 7
BP during sleep
SBP (mmHg) 128.8 ± 1
DBP (mmHg) 77.0 ± 5
24-h BP
SBP (mmHg) 140.5 ± 1
DBP (mmHg) 84.5 ± 7
SBP, systolic blood pressure; DBP, diastolic blood pressure. Mean ± S.D.
a p < 0.01 vs. Valsartan-M (by BonferronieDunn test).
b p < 0.05 vs. at the initiation of the study (by paired t-test).
c p < 0.01 vs. at the initiation of the study (by paired t-test).of valsartan switched to 20mg/day of olmesartan). An adherence to
treatment was checked at every clinic visit.
The second 24-h BPwas assessed at 4 months after changing the
dose regimen. Serum creatinine was measured at the initiation and
end of the study, and the estimated glomerular ﬁltration rate (eGFR,
ml/min/1.73 m2) was calculated as follows; 194  serum
creatinine1.094  age0.287  0.739 (if female) (16).
Acceptable criteria of ABPMwere (i) >24 hmeasurement and (ii)
at least 80% of available readings. Patients who completed the
protocol without changing antihypertensive drugs and had good
adherence without changing other drugs were included for anal-
ysis. Seventy-seven patients completed the study (Fig. 1), and their
data were analyzed.
2.3. Statistical analyses
This study was performed by pre-post comparison design,
because there was not a non-dipper group who continued to take
valsartan in the morning as a control. It was estimated that an
enrollment of 10 patients per group would provide a power of at
least 80% (alpha ¼ 0.05, two-sided) to detect 10% decline of night-
time BP status compared to the baseline, with 10% of standard
deviation.
Characteristics of patients (other than age and body weight)
were analyzed by Fisher's exact test, followed by pairwise com-
parisons. Age and body weight, and proﬁles of BP at the initiation of
the study were compared by one-way analysis of variance with
post-hoc BonferronieDunn test.
Changes in BP, serum creatinine and eGFR were compared using
the paired t-test (the baseline vs. 4 months). Correlation between
BP and serum creatinine (or eGFR) was assessed using Pearson's
correlation coefﬁcient. p < 0.05 was considered signiﬁcant. All
calculations were undertaken using SPSS ver11 (SPSS Japan, Tokyo,
Japan) and EZR (a modiﬁed version of R commander, Saitama
Medical Center, Jichi Medical University, Saitama, Japan).zation group
-E (n ¼ 11) Olmesartan-M (n ¼ 11) Olmesartan-E (n ¼ 12)
.2 7.8 ± 1.2 7.1 ± 1.5
.3a 4.3 ± 4.0a 1.2 ± 5.0a
.6 143.8 ± 9.0 140.2 ± 12.9
.0 86.3 ± 6.9 82.3 ± 8.5
3.0a 136.8 ± 9.0a 138.5 ± 15.4a
.3 79.6 ± 4.4 79.6 ± 8.7
.8 142.2 ± 8.2 139.6 ± 13.0
.4 84.6 ± 5.7 81.7 ± 8.1
.3 8.3 ± 0.9 7.6 ± 1.1
.8c 10.1 ± 6.4b 6.4 ± 10.4b
4.3 140.1 ± 10.8 139.2 ± 18.0
.4 83.2 ± 5.9 82.8 ± 7.9
2.6 125.7 ± 10.6c 130.3 ± 18.3b
.9 72.3 ± 7.6c 75.3 ± 9.1
3.8 137.1 ± 9.8 138.7 ± 18.4
.2 80.9 ± 5.9b 79.7 ± 9.1
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In this study, mean number of observation points obtained for
calculation of BP dipping was 33 during waking hours and 8 during
sleep. The availabilities of ABPM measurements during waking
hours and sleep were more than 95%.
The characteristics of hypertensive patients and BP proﬁles at
the initiation of the study are shown in Tables 1 and 2. The per-
centage of hypertensive patients with diabetes mellitus was
signiﬁcantly (p < 0.05) greater in the olmesartan-E group (33%)
than in the valsartan-M group (5%). While the percent reduction in
SBP at night-time compared to SBP at waking hours was signiﬁ-
cantly (p < 0.01) lower and SBP during sleep was signiﬁcantly
(p < 0.01) higher in the valsartan-E, olmesartan-M and olmesartan-
E groups than in the valsartan-M group, SBP during waking hours
and mean 24-h SBP did not signiﬁcantly differ among the four
groups. No signiﬁcant differences were observed in any parameters
(the characteristics of patients and BP proﬁles at the initiation of
the study shown in Tables 1 and 2) among the valsartan-E, olme-
sartan-M and olmesartan-E groups.Fig. 2. SBP changes in ABPM study after switching to (a) evening dosing of valsartan, (b)
patients with non-dipper BP pattern during morning dosing of valsartan.
Mean ± S.D., n ¼ 11e12.BP proﬁles at the end of the study are also shown in Table 2.
Comparing BP values between before and after changing the dose
regimen in each group, the changes in mean value of BP at the end
of the study were 4.1 mmHg (SBP) and 2.2 mmHg (DBP) during
sleep, and þ7.9 mmHg (SBP) and þ4.2 mmHg (DBP) during waking
hours in the valsartan-E group (Fig. 2a). In the olmesartan-M and
olmesartan-E groups, the mean value of BP decreased signiﬁcantly
during sleep (SBP, 11.1 mmHg, DBP, 7.4 mmHg, p < 0.01 and
SBP, 8.3 mmHg, p < 0.05, respectively) (Fig. 2b, c). The changes in
mean value of BP during waking hours were 3.7 mmHg (SBP)
and 3.1 mmHg (DBP) in the olmesartan-M group, and
were 1.4 mmHg (SBP) and þ0.4 mmHg (DBP) in the olmesartan-E
group. The percent reduction in SBP during night-time compared to
SBP during waking hours signiﬁcantly increased at 4 months after
changing the dose regimen in each group as follows; 2.4 ± 6.3 to
10.5 ± 3.8% in the valsartan-E (p < 0.01), 4.3 ± 4.0 to 10.1 ± 6.4% in
the olmesartan-M (p < 0.05) and 1.2 ± 5.0 to 6.4 ± 10.4% in the
olmesartan-E (p< 0.05) groups (Fig. 3). The number of patients with
a dipper BP pattern was 7/11 (64%) in the valsartan-E, 5/11 (46%) in
the olmesartan-M and 5/12 (42%) in the olmesartan-E groups.morning dosing of olmesartan and (c) evening dosing of olmesartan in hypertensive
Fig. 3. Changes in SBP reduction during sleep at 4 months after switching the dose regimen in hypertensive patients with non-dipper BP rhythm during morning dosing of
valsartan.
Mean ± S.D.
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in the olmesartan-treated groups, and eGFR signiﬁcantly elevated
(p < 0.05) in the olmesartan-M group and tended to elevate
(p ¼ 0.06) in the olmesartan-E group after dosing the drug for
4 months (Table 3). Renal function was not signiﬁcantly improved
in the valsartan-E group. Positive correlations were detected be-
tween SBP during sleep and serum creatinine in all (p < 0.05) and
non-dipper (p ¼ 0.06) patients (Fig. 4a). In addition, there were
negative correlations between SBP during sleep and eGFR in all
(p < 0.05) and non-dipper (p < 0.05) patients (Fig. 4b). No signiﬁ-
cant correlations were observed between other BP measurements
(SBP during waking hours, DBP during sleep and waking hours,
24-h SBP and DBP) and serum creatinine (or eGFR).
4. Discussion
In this study, the percentage of patients with a non-dipper BP
pattern given amorning dose of valsartan for >2months was 43.5%,
which is similar to those reported in other studies (45.7e57.8%)
(11,12).
The effect of antihypertensive drugs can be inﬂuenced by a
dosing-time, and appropriate timing of dosing is likely to correct an
abnormal BP pattern (17). Chronotherapeutic studies in patients
with a non-dipping BP pattern have shown that switching all
antihypertensive drugs from morning to evening dosing, or adding
a new drug in the evening, corrected the abnormal BP pattern in
15% and 41% of patients, respectively (9,10). In this study, in hy-
pertensive patients with a non-dipper BP pattern, a dipper BP
pattern was obtained in 64% of subjects after switching from
morning to evening dosing of valsartan without changing its dose.
Thus, this study also showed that the chronotherapeutic approachTable 3
Changes in (a) serum creatinine and (b) eGFR level during the 4months of the study.
(n) 0 4 months p
(a) Serum creatinine (mg/dL)
Reference group
Valsartan-M 43 0.75 ± 0.19 0.75 ± 0.18 0.49
Randomization group
Valsartan-E 11 0.73 ± 0.17 0.74 ± 0.20 0.95
Olmesartan-M 11 0.77 ± 0.20 0.74 ± 0.20 0.02
Olmesartan-E 12 0.84 ± 0.24 0.79 ± 0.23 0.04
(b) eGFR (mL/min/1.73 m2)
Reference group
Valsartan-M 43 77.0 ± 19.5 77.7 ± 19.6 0.53
Randomization group
Valsartan-E 11 77.8 ± 12.3 78.9 ± 16.2 0.74
Olmesartan-M 11 66.7 ± 11.9 70.6 ± 14.2 0.04
Olmesartan-E 12 65.7 ± 15.6 69.4 ± 16.1 0.06
Mean ± S.D.of valsartan could change a non-dipper BP pattern in hypertensive
patients during morning treatment with the drug to a dipper BP
pattern.
SBP slightly decreased during sleep (mean, 4.1 mmHg) after
switching from morning to evening dosing in the valsartan-E
group. However, SBP slightly increased during waking hours
(mean, þ7.9 mmHg), and consequently, the dipping state was
improved in this group. Dipper BP patterns were also obtained in
42e46% of patients in olmesartan-treated groups. In contrast to the
valsartan-E group, SBP signiﬁcantly decreased during sleep and
slightly decreased during waking hours in the olmesartan-M and
olmesartan-E groups. Therefore, it is likely that the inﬂuence of
valsartan after evening dosing on daily BP pattern was different
from those of olmesartan after morning and evening dosings under
the present condition. Our previous study in SHR-SP rats showed
that plasma concentrations of valsartan after dosing during an
inactive period were higher than those after dosing during an
active period, which in turn caused the dosing time-dependent
changes in the duration of BP-lowering effects (1). However,
although plasma concentrations of olmesartan also varied with a
dosing-time, the duration of BP-lowering effects were not inﬂu-
enced (1). Compared with valsartan, olmesartan is reported to
dissociate slowly from the AII receptors of vascular tissue (14),
which partially explains the chronotherapeutic differences be-
tween valsartan and olmesartan observed in the previous animal
and present human studies.
The chronotherapeutic effects of olmesartan in hypertensive
patients have been published, and conﬂicting data observed. Some
research groups (18,19) found that, compared withmorning dosing,
evening dosing of olmesartan was a better dose regimen for the
treatment of hypertension, whereas other research groups (20,21)
did not support the merits of chronotherapy of olmesartan. In
this study, the percent of dipper BP patternwas similar between the
olmesartan-M (46%) and olmesartan-E (42%) groups, which sug-
gests that the inﬂuence of a dosing-time of olmesartan on BP dip-
ping state was small in hypertensive patients with a non-dipper BP
pattern during valsartan treatment at morning. We do not have
deﬁnitive explanations for apparent diverse ﬁndings, and further
clinical studies are needed to conﬁrm the chronotherapeutic effects
of olmesartan.
The previous study showed that the duration of the antihy-
pertensive effect of valsartan was longer after dosing during an
inactive period than after dosing during an active period in SHR-SP
and, consequently, the survival period of the rats was longer after
dosing during an inactive period (1). In addition, such chro-
notherapeutic effects were not detected for olmesartan in the
animal study. Based on these animal data, we speculated that the
protective effect of valsartan (but not olmesartan) against
hypertension-induced organ damage differs between morning
Fig. 4. Correlation between SBP during sleep, and (a) serum creatinine and (b) eGFR in all patients and non-dipper patients during morning dosing of valsartan. Data at the
initiation and end of the study were included. For the dipper patients (valsartan-M group), only the values at the initiation of the study were available because 2nd ABPM was not
performed at the end of the study in this group.
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corrected in 64% of the patients in the valsartan-E group, and
therefore, we anticipated that renal function might be improved
after switching from morning to evening dosing. However, serum
creatinine did not signiﬁcantly decrease or eGFR did not signiﬁ-
cantly increase at 4 months after switching the dose regimen in
the valsartan-E group. Elevated night-time BP (especially SBP)
(5,22) and a non-dipper BP pattern (23) are potent risk factors for
declines in GFR. However, whether a reduction of night-time BP or
a dipper BP pattern can be a therapeutic target to prevent pro-
gression of renal disease should still be better deﬁned (6). After
switching from morning to evening dosing, SBP slightly decreased
during sleep and slightly increased during waking hours in the
valsartan-E group, and consequently, the dipping state was
improved in this group (64%). On the other hand, dipper BP pat-
terns were detected in 46% of patients in the olmesartan-M group
and in 42% of patients in the olmesartan-E group. However, in
contrast to the valsartan-E group, serum creatinine decreased and
eGFR increased in the olmesartan-M and-E groups. SBP during
sleep signiﬁcantly decreased in the olmesartan-M and
olmesartan-E groups. In addition, a positive correlation between
SBP during sleep and serum creatinine, and a negative correlation
between SBP during sleep and the eGFR were detected. Based on
these data, it is speculated that, although a dipper BP pattern was
obtained in many patients in the valsartan-E group, BP reduction
at night was too small to improve renal function under the present
condition, which is comparable with the idea that a reduction of
night-time BP rather than a dipper BP pattern is more adequate
target to prevent progression of renal disease. Hermida et al. re-
ported that the dosing of valsartan at bedtime reduced BP duringsleep and improved renal function in hypertensive patients (12),
ﬁndings which were different from those in this study. However,
the daily dose of valsartan was 160 mg in their study and
40e80 mg in this study, which could have caused the diverse
chronotherapeutic effects of valsartan. Therefore, whether the
chronotherapeutic effects of valsartan are altered by the dose of
the drug remains to be determined.
4.1. Limitation of this study
The number of patients was relatively small in this study, which
might lead to an incorrect conclusion. In addition, because the
changes in serum creatinine and eGFR after changing the dose
regimen were small, it remains to be determined whether the
chronotherapeutic approach improves the prognosis of these pa-
tients. Further study with a longer duration in a larger number of
patients is needed to conﬁrm the chronotherapeutic differences
between valsartan and olmesartan.
In summary, the present ﬁndings suggest that a dipper BP
pattern could be obtained after switching frommorning to evening
dosing of valsartan, and switching to morning and evening dosing
of olmesartan, in hypertensive patients with a non-dipper BP
pattern during morning treatment with valsartan. Morning and
evening olmesartan, but not evening valsartan improved renal
function in these patients. Therefore, it is speculated that, in hy-
pertensive patients with a non-dipper BP pattern during morning
treatment with valsartan, an increased dose of the drug is needed
to improve renal function, irrespective of dosing-time. On the other
hand, olmesartan (equivalent dose of valsartan) might improve
renal function after dosing at morning or evening in these patients.
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